Humacyte, Inc.
HUMA
$1.41
$0.021.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -145.02% | -18.45% | 55.33% | 33.54% | 222.71% |
| Total Depreciation and Amortization | -2.29% | -1.11% | 2.92% | 4.55% | 2.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 86.25% | 205.26% | -137.38% | -63.49% | -908.95% |
| Change in Net Operating Assets | 86.36% | -232.35% | -220.71% | -134.45% | -105.24% |
| Cash from Operations | 12.23% | 1.70% | -4.35% | -24.06% | -4.59% |
| Capital Expenditure | 23.25% | 38.10% | 94.75% | -208.70% | 41.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 23.25% | 38.10% | 94.75% | -208.70% | 41.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 4.61% | -12.75% | -12.89% | -13.93% |
| Issuance of Common Stock | -50.83% | 7.39% | 1,151.92% | 310.80% | 9.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -3,705.92% | -5,040.28% | 44.26% | -- |
| Cash from Financing | -50.10% | 12.09% | -5,352.18% | 563.81% | -25.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.93% | 27.26% | -198.12% | -13.09% | -48.91% |